Mode
Text Size
Log in / Sign up
Phase 3 Completed N=41 Randomized Quadruple-blind Treatment

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Primary Hyperparathyroidism
Source: ClinicalTrials.gov NCT02525796 ↗
Enrolled (actual)
41
Serious AEs
0.0%
Results posted
May 2023
Primary outcomePrimary: Change in Parathyroid Hormone Levels — 4.0; -3.7; 0.8 pg/mL — p=0.84
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium levels in primary hyperparathyroidism.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Parathyroid Hormone Levels
4.0; -3.7; 0.8 0.84
SECONDARY
Change in Calcium Levels
0.1; 0.0; 0.1 0.82

Eligibility Criteria

Inclusion Criteria

  • physician diagnosis of active P-HPTH (Serum calcium > upper limit of reference range and serum PTH > ULRR; or Serum Calcium > ULRR AND serum PTH > 30 pg/mL; or Serum Calcium within 0.2 mg/dL of the ULRR and PTH>ULRR).
  • negative pregnancy test in women aged 18-45

Exclusion Criteria

  • estimated glomerular filtration rate 5.0 mmol/L
  • age 80 years
  • diabetes that is not well controlled (HbA1c>8%)\
  • liver failure
  • heart failure
  • history of myocardial infarction or stroke
  • active use of lithium
  • active chronic inflammatory conditions (such as inflammatory bowel disease, rheumatoid arthritis, sarcoidosis)
  • initiation within 3 months of bisphosphonates or cinacalcet
  • need for imminent parathyroidectomy (within the next 6-8 weeks) as determined by their endocrinologist or surgeon
  • absolute serum calcium >13.0 mg/dL
  • positive pregnancy test on any of the study visits for women ages 18-45.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02525796). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search